Beginners

Mitrade Insights is dedicated to providing investors with rich, timely and most valuable financial information to help investors grasp the market situation and find timely trading opportunities.

2021

Best News & Analysis Provider

FxDailyInfo

2022

Best Forex Educational Resources Global

International Business Magazine

Insights

News

Stocks

Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth

Source Motley_fool

Explore the exciting world of Kiniksa Pharmaceuticals (NASDAQ: KNSA) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
*Stock prices used were the prices of May 28, 2025. The video was published on Jul. 2, 2025.

Should you invest $1,000 in Kiniksa Pharmaceuticals International right now?

Before you buy stock in Kiniksa Pharmaceuticals International, consider this:

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Kiniksa Pharmaceuticals International wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $697,627!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $939,655!*

Now, it’s worth noting Stock Advisor’s total average return is 1,045% — a market-crushing outperformance compared to 178% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of June 30, 2025

Anand Chokkavelu, CFA has no position in any of the stocks mentioned. Karl Thiel has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Kiniksa Pharmaceuticals International, Plc. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.

Recommended Articles

Bitcoin Must Clear This Critical Cost Basis Level For Continued Upside, Analyst Says In a recent CryptoQuant Quicktake post, contributor Crazzyblockk highlighted key Bitcoin (BTC) cost basis zones that the leading cryptocurrency must clear – or avoid breaking below – to

Author NewsBTC

4 Month 23 Day Wed

In a recent CryptoQuant Quicktake post, contributor Crazzyblockk highlighted key Bitcoin (BTC) cost basis zones that the leading cryptocurrency must clear – or avoid breaking below – to

Ethereum Price Action Turns Bearish — Risk of Near-Term Correction Ethereum price started a fresh increase above the $2,450 zone. ETH is now correcting gains from $2,520 and might slip to test the $2,320 zone. Ethereum started a fresh upward move above the $2,350

Author NewsBTC

6 Month 27 Day Fri

Ethereum price started a fresh increase above the $2,450 zone. ETH is now correcting gains from $2,520 and might slip to test the $2,320 zone. Ethereum started a fresh upward move above the $2,350

Ethereum Price Tests Resistance — Breakout Could Spark Rally Ethereum price started a fresh increase above the $2,480 zone. ETH is now consolidating gains and might soon aim for a move above the $2,520 resistance. Ethereum started a fresh upward move above the

Author NewsBTC

6 Month 30 Day Mon

Ethereum price started a fresh increase above the $2,480 zone. ETH is now consolidating gains and might soon aim for a move above the $2,520 resistance. Ethereum started a fresh upward move above the

XRP Roadmap To $8.5: Why The Next Impulse Could Start Soon XRP is starting to draw attention again as signs of a potential breakout begin to take shape. With market sentiment gradually shifting and XRP holding key support levels, analysts suggest that the

Author NewsBTC

Yesterday 02: 16

XRP is starting to draw attention again as signs of a potential breakout begin to take shape. With market sentiment gradually shifting and XRP holding key support levels, analysts suggest that the

Ethereum Price Forecast: ETH surpassed key milestones in June, but price remains stagnant Ethereum (ETH) is down 3% on Tuesday, extending its decline from June, which ended on a negative note despite key bullish catalysts in the month, including high exchange-traded funds (ETFs) inflows, record-breaking buying from accumulation addresses, and public companies launching ETH treasuries.

Author FXStreet

Yesterday 02: 18

Ethereum (ETH) is down 3% on Tuesday, extending its decline from June, which ended on a negative note despite key bullish catalysts in the month, including high exchange-traded funds (ETFs) inflows, record-breaking buying from accumulation addresses, and public companies launching ETH treasuries.

Popular Symbols